- Home
- / Tollys
Tollys
Total Funding
$6.8 M
Tollys Summary
Company Summary
- Overview
- Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company offers TL-532, new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically, and highly specific to the TLR3 receptor.
- Type
- Private
- Status
- Active
- Founded
- 2015
- HQ
- Lyon, FR | view all locations
- Website
- http://tollys.fr/
- Cybersecurity rating
Table of Contents
LocationsView all
2 locations detected
Lyon, Auvergne-Rhône-Alpes HQ
France
41 Quai Fulchiron
Lyon, Auvergne-Rhône-Alpes
France
60 Av. Rockefeller
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026